Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06584396 · ClinicalTrials.gov registry record
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study
A clinical trial of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 140
- Enrollment target
- 1
- Study location
NCT06584396: Active study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06584396 is a study of Breast Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06584396, a study of Breast Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the skin and surrounding soft tissue that is removed during an implant reconstruction after a mastectomy.
Primary Outcome
The nanomechanical properties will be presented as a histogram that describes the characteristics of the sample. For each skin sample, summary statistics including mean (median), standard deviation, skewness, and range, mode, etc. will be used to describe the nanomechanical properties. Wilcoxon rank sum test or Fisher's exact test will be used to study the association between the summarized nanomechanical properties and clinical factors or outcomes. Pearson correlation coefficients will be used
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2027-08-30 |
What the registry record for NCT06584396 still lists
NCT06584396 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06584396 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06584396 about?
NCT06584396 is a clinical study titled "Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study". This study evaluates the skin and surrounding soft tissue that is removed during an implant reconstruction after a mastectomy.
What is the current status of trial NCT06584396?
This trial is currently active not recruiting. The enrollment target is 140 participants. The study started on 2023-09-20. Estimated completion is 2027-08-30.
What conditions does trial NCT06584396 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT06584396?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06584396?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06584396 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06584396's enrollment target sits among peer trials
140 48th of 106 higher than 57 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI